Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Northstar Signs MOU to Mine High Grade Zone 2 at Cam Copper Mine (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Merck & Co Inc MRK

Healthcare
Merck & Co., Inc. is a global health care company. It offers health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. Its Pharmaceutical segment includes human health pharmaceuticals and vaccine products. Human health pharmaceutical products include therapeutic and preventive agents, sold by prescription, for the treatment of human... see more

Recent & Breaking News (NYSE:MRK)

Merck's Q3 Earnings Preview

Benzinga.com  October 24, 2018

11 Stocks That Moved From ESMO 2018

Benzinga.com  October 22, 2018

Merck’s KEYTRUDA (pembrolizumab) Significantly Improved Overall Survival Compared to Standard of Care, as Monotherapy and in Combination with Chemotherapy, as First-Line Treatment for Patients with Recurrent or Metastatic Head and Neck Cancer

Business Wire October 22, 2018

European Medicines Agency Adopts Positive Opinion for Merck’s KEYTRUDA® (pembrolizumab) as Adjuvant Therapy in Melanoma

Business Wire October 22, 2018

SOLO-1 Phase 3 Trial Demonstrates LYNPARZA® (olaparib) Maintenance Therapy Cut the Risk of Disease Progression or Death by 70 Percent in Patients with Newly-Diagnosed, Advanced BRCA-Mutated Ovarian Cancer

Business Wire October 21, 2018

First Presentation of Early Data for Merck’s Investigational STING Agonist (MK-1454) in Patients with Advanced Solid Tumors or Lymphomas at ESMO 2018 Congress

Business Wire October 20, 2018

The Daily Biotech Pulse: Novartis Positive Liver Drug Trials, Krytstal Prices Offering, LogicBio To Debut

Benzinga.com  October 19, 2018

Merck’s KEYTRUDA® (pembrolizumab) in Combination with Pfizer’s Inlyta® (axitinib) Significantly Improved Overall Survival (OS) and Progression-free Survival (PFS) as First-Line Therapy for Advanced or Metastatic Renal Cell Carcinoma

Business Wire October 18, 2018

Merck Announces Appointment of Jim Scholefield as Chief Information and Digital Officer

Business Wire October 17, 2018

U.S. FDA Grants LYNPARZA® (olaparib) Orphan Drug Designation for Pancreatic Cancer

Business Wire October 16, 2018

Global Survey and Documentary Film Expose Emotional Impact of Multiple Sclerosis

Canada NewsWire October 11, 2018

The Daily Biotech Pulse: Clinical Hold Lifted Off Crispr's Gene-Edited Therapy, Endra To Offer Shares

Benzinga.com  October 11, 2018

The Daily Biotech Pulse: Novartis Blood Disorder Drug Improves Patient Outcomes, Audentes To Offer Shares

Benzinga.com  October 10, 2018

Merck to Hold Third-Quarter 2018 Sales and Earnings Conference Call on October 25

Business Wire October 10, 2018

Merck’s Broad Oncology Pipeline to Be Highlighted at ESMO 2018 Congress

Business Wire October 9, 2018

The Daily Biotech Pulse: AtriCure's Guidance, Guardant Health And Kodiak To Debut

Benzinga.com  October 4, 2018

A Peek Into The Markets: US Stock Futures Drop Ahead Of Jobless Claims, Factory Orders Data

Benzinga.com  October 4, 2018

Merck Announces Week 96 Data from Pivotal Phase 3 DRIVE-AHEAD Study Evaluating DELSTRIGO™ (doravirine / lamivudine / tenofovir disoproxil fumarate) for the Treatment of HIV-1 in Treatment-Naïve Patients

Business Wire October 4, 2018

Merck’s HIV Therapy DELSTRIGO™ (doravirine / lamivudine / tenofovir disoproxil fumarate) Meets Primary Efficacy Endpoint in Phase 3 DRIVE-SHIFT Study Evaluating Switch to DELSTRIGO from Other Antiretroviral Treatment Regimens

Business Wire October 4, 2018

The Daily Biotech Pulse: Endologix's Q3 Sales, Obseva's Positive Trial Results, Kala To Offer Shares

Benzinga.com  October 3, 2018
USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse
Later
Participate
Not interested